ReportsnReports.com adds “Stem Cell Therapy Market in Asia-Pacific to 2018 – Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity” to its…(PRWeb December 21, 2012)Read the full story at…
ReportsnReports.com adds “Stem Cell Therapy Market in Asia-Pacific to 2018 – Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity” to its…(PRWeb December 21, 2012)Read the full story at…
26 Mobile Hydraulic Cranes Will Be Positioned Side-By-Side Hoisting Flags In The Air As A Tribute To Honor The Lives Of The Children and Adult Heroes.(PRWeb December 21, 2012)Read the full story at http://www.prweb.com/releases/2012/12/prweb10264401…
Stemedica Cell Technologies, Inc., a leading manufacturer of adult ischemia tolerant allogeneic stem cells and stem cell factors announced that the Company has signed an agreement with The Scripps…(PRWeb December 21, 2012)Read the full story at ht…
The BioTechniques Digital Spotlight Series launches this month with a special digital-only issue on Transfection. Future issues will cover PCR, Cell Culture, Microscopy, Next-generation Sequencing,…(PRWeb December 20, 2012)Read the full story at h…
The BioTechniques Digital Spotlight Series launches this month with a special digital-only issue on Transfection. Future issues will cover PCR, Cell Culture, Microscopy, Next-generation Sequencing,…(PRWeb December 20, 2012)Read the full story at h…
Landmark clinical trial begins for rapid DNA testing and personalized anti-blood clotting drugs.(PRWeb December 20, 2012)Read the full story at http://www.prweb.com/releases/2012/12/prweb10252073.htm
MUSA is pleased to announce that they’ve documented and deployed a Citrix platform for GxP-hosted and FDA-compliant applications in Validated Cloud using the Citrix XenApp and Netscaler lines of…(PRWeb December 20, 2012)Read the full story at ht…
MUSA is pleased to announce that they’ve documented and deployed a Citrix platform for GxP-hosted and FDA-compliant applications in Validated Cloud using the Citrix XenApp and Netscaler lines of…(PRWeb December 20, 2012)Read the full story at ht…
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
 |
ADVERTISE HERE |
This
newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Simple flat-rate database subscription
| ||||||||||||||||||||
| Ultimate Plan | Premium Plan |
Basic Plan | |
| One year | $1,995  |
$1,795  |
$1,095 |
| One month | $525 |
$425 |
$325 |
| 48 hours | $95 |
$75 |
|
| Plan comparison Site tour Discount schedule Contact |
|||
Drug Patent Expirations for December 12 2012
DrugPatentWatch Serves Your Competitive Intelligence
|
||||||||||||||||||||||||||||||||||||||